Traders Purchase High Volume of VistaGen Therapeutics Put Options (NASDAQ:VTGN)

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) saw unusually large options trading activity on Friday. Traders bought 2,482 put options on the company. This represents an increase of 31% compared to the typical volume of 1,893 put options.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on VTGN. William Blair reissued a “market perform” rating on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Maxim Group reissued a “hold” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of VistaGen Therapeutics in a report on Wednesday, October 8th. Jefferies Financial Group restated a “hold” rating and set a $0.90 target price (down previously from $15.00) on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Finally, Stifel Nicolaus lowered shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price target on the stock. in a research note on Wednesday, December 17th. Four investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $0.95.

VistaGen Therapeutics Trading Down 1.1%

NASDAQ VTGN traded down $0.01 on Friday, hitting $0.72. 1,375,715 shares of the company’s stock were exchanged, compared to its average volume of 799,273. The stock has a 50-day moving average of $3.74 and a 200-day moving average of $3.23. The stock has a market cap of $28.43 million, a price-to-earnings ratio of -0.38 and a beta of 0.56. VistaGen Therapeutics has a 52 week low of $0.68 and a 52 week high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The firm had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.16 million. As a group, analysts predict that VistaGen Therapeutics will post -1.77 earnings per share for the current year.

Hedge Funds Weigh In On VistaGen Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in VTGN. Millennium Management LLC acquired a new position in shares of VistaGen Therapeutics during the third quarter worth $73,000. Bank of America Corp DE grew its position in VistaGen Therapeutics by 926.0% during the 3rd quarter. Bank of America Corp DE now owns 34,657 shares of the company’s stock worth $123,000 after acquiring an additional 31,279 shares during the last quarter. Boothbay Fund Management LLC increased its holdings in VistaGen Therapeutics by 10.8% in the 3rd quarter. Boothbay Fund Management LLC now owns 197,024 shares of the company’s stock worth $699,000 after purchasing an additional 19,166 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new position in VistaGen Therapeutics in the third quarter valued at about $39,000. Finally, Occudo Quantitative Strategies LP bought a new stake in shares of VistaGen Therapeutics during the third quarter worth about $152,000. Institutional investors own 78.39% of the company’s stock.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.